We are live on ! Find out more
ATHE

Alterity Therapeutics
ATHE

7 hedge funds and large institutions have $163K invested in Alterity Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 7 → 7 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

37% less capital invested

Capital invested by funds: $260K → $163K (-$97.2K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAS
Coppell Advisory Solutions
Texas
+$23

Top Sellers

Rank Fund Capital Flow
1
OMC
Old Mission Capital
Illinois
-$94.5K
2
Morgan Stanley
Morgan Stanley
New York
-$3.69K

ATHE Hedge Fund Activity: Q2 2023 in Review

7 of the 6,373 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2023, worth a combined $163K — down 37% from $260K a quarter earlier.

Fund positioning in ATHE was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Coppell Advisory Solutions, opening a new position worth an estimated $23. The largest seller was Old Mission Capital, exiting entirely with an estimated $94.5K sold.

  • 7 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $163K of Alterity Therapeutics stock for Q2 2023, down 37% quarter-over-quarter.
  • 1 fund opened new Alterity Therapeutics positions in Q2 2023 and 1 closed out, a net change of 0 holders.
  • The largest Alterity Therapeutics buyer in Q2 2023 was Coppell Advisory Solutions, an estimated $23 added.
  • The largest Alterity Therapeutics seller in Q2 2023 was Old Mission Capital, an estimated $94.5K sold.

Based on aggregated 13F filings for Q2 2023.